Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.14694 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influence of sodium-glucose cotransporter 2 inhibitors on the triglyceride-glucose index in acute myocardial infarction patients with type 2 diabetes mellitus.
Cardiovasc Diagn Ther
December 2024
Department of Cardiology, Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: As a novel oral anti-hyperglycemic agent, sodium-glucose cotransporter 2 inhibitors (SGLT2-i) have been demonstrated to improve cardiovascular outcomes in acute myocardial infarction (AMI) patients with type 2 diabetes mellitus (T2DM). However, the mechanism responsible for the beneficial effects remains unclear. Recently, extensive studies have demonstrated a close relationship between elevated fasting triglyceride-glucose (TyG) index and the risk of AMI.
View Article and Find Full Text PDFEvaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD).
Diabetol Metab Syndr
January 2025
Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Background: Our meta-analysis fills gaps by assessing sodium-glucose cotransporter-2 (SGLT2) inhibitors' renal outcomes in chronic kidney disease (CKD) patients including long-term effects and the subgroup analyses of estimated glomerular filtration rate (eGFR) values and follow-up times.
Methods: The literature search of relevant randomized controlled trials (RCTs) was conducted in Medline, Embase, and the Cochrane Central from the inception to 8 June 2023 on patients with CKD treated with SGLT2 inhibitors. We selected medical subject heading (MeSH) terms and free text terms associated with gliflozin and RCT.
Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis.
J Clin Med
November 2024
Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, initially designed for type 2 diabetes, promote glucose excretion and lower blood glucose. Newer analogs like empagliflozin and dapagliflozin improve cardiovascular outcomes through mechanisms other than glycemic control, including blood pressure reduction and anti-inflammatory effects. Given the high cardiovascular risk present in diabetes, our study aims to emphasize the cardioprotective benefits of SGLT-2 inhibitors as a preventive therapy for heart failure (HF) in high-risk T2DM patients.
View Article and Find Full Text PDFEmpagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.
JAMA Ophthalmol
December 2024
Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Empagliflozin may reduce the risk of diabetic retinopathy (DR) by preventing the loss of retinal pericytes, but its effectiveness compared to DPP4 inhibitors in patients with type 2 diabetes (T2D) is not well established.
- A study was conducted using U.S. insurance claims data from 2014 to 2019, focusing on adults with T2D who were newly prescribed either empagliflozin or a DPP4 inhibitor, and looking at the incidence of nonproliferative DR and its progression.
- Results showed that among matched patient pairs, empagliflozin's impact on the rates of incident DR and progression was analyzed, with significant data collected over an average
A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database.
Sci Rep
December 2024
Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4, Daigaku-nishi, Gifu, 501-1196, Japan.
Article Synopsis
- * The study identified seasonal trends in adverse events like dehydration, cerebral infarction, urinary tract infections, and ketoacidosis linked to six SGLT2 inhibitors prescribed in Japan.
- * Findings showed dehydration-related issues were most common in summer and winter, with a peak for cerebral infarction in February, suggesting healthcare professionals should be vigilant about dehydration risks throughout the year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!